(NASDAQ: BEAM) Beam Therapeutics's forecast annual revenue growth rate of -17.37% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 40.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.76%.
Beam Therapeutics's revenue in 2023 is $60,920,000.On average, 3 Wall Street analysts forecast BEAM's revenue for 2023 to be $3,016,519,693, with the lowest BEAM revenue forecast at $1,447,952,620, and the highest BEAM revenue forecast at $5,429,822,325. On average, 3 Wall Street analysts forecast BEAM's revenue for 2024 to be $3,016,519,693, with the lowest BEAM revenue forecast at $1,447,952,620, and the highest BEAM revenue forecast at $5,429,822,325.
In 2025, BEAM is forecast to generate $2,171,928,930 in revenue, with the lowest revenue forecast at $2,171,928,930 and the highest revenue forecast at $2,171,928,930.